Clinical and economic outcomes in medicare beneficiaries with stage 3 or stage 4 chronic kidney disease and anemia: The role of intravenous iron therapy

Journal of Managed Care Pharmacy

Volumn 16, Issue 8, 2010, Pages 605-615

  Knight, Tyler G ^a   Ryan, Kellie ^a   Schaefer, Caroline P ^a   D'Sylva, Lynell ^b   Durden, Emily D ^a  

^a Covance Market Access Services Inc   (United States)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS GLUCONATE; IRON; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; DISEASE COURSE; FEMALE; FERRITIN BLOOD LEVEL; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICARE; TRANSFERRIN BLOOD LEVEL; TREATMENT OUTCOME;

EID: 77958585184     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2010.16.8.605     Document Type: Article

References (42)

1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038-47. Available at: http://jama.ama-assn.org/cgi/content/full/298/17/2038. Accessed September 17, 2010.
2. Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis. 2007;14(1):82-99. (Pubitemid 46014531)
3. Weiner DE. Causes and consequences of chronic kidney disease: implications for managed health care. J Manag Care Pharm. 2007:13(3 Suppl):S1-S9. Available at: http://www.amcp.org/data/jmcp/Supplement.pdf. (Pubitemid 46730890)
4. Thorp ML, Johnson ES, Yang X, Petrik AF, Platt R, Smith DH. Effect of anaemia on mortality, cardiovascular hospitalizations, and end-stage renal disease among patients with chronic kidney disease. Nephrology (Carlton). 2009;14(2):240-46.
5. Erslev AJ. Erythropoietin. N Eng J Med. 1991;324(19):1339-44.
6. Valderrabáno F. Quality of life benefits of early anaemia treatment. Nephrol Dial Transplant. 2000;15(Suppl 3):S23-S28. Available at: http://ndt.oxfordjournals.org/cgi/reprint/15/suppl-3/23?view=long&pmid= 11032354. Accessed September 17, 2010.
7. Al-Khoury S, Afzali B, Shah N, et al. Diabetes, kidney disease and anaemia: time to tackle a troublesome triad? Int J Clin Pract. 2007;61(2):281-89. (Pubitemid 46271291)
8. Dowling TC. Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview. Am J Health Syst Pharm. 2007;64(13 Suppl 8):S3-S7. (Pubitemid 47025528)
9. Lefebvre P, Duh MS, Buteau S, Bookhart B, Mody SH. Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease. J Am Soc Nephrol. 2006;17(12):3497-502. Available at: http://jasn.asnjournals.org/ cgi/reprint/17/12/3497. Accessed September 17, 2010. (Pubitemid 44865292)
10. Nissenson AR, Wade S, Goodnough T, Knight K, Dubois RW. Economic burden of anemia in an insured population. J Manag Care Pharm. 2005;11(7):565-74. Available at: http://www.amcp.org/data/jmcp/Original%20Research-565-574.pdf.
11. Jones M, Ibels L, Schenkel B, Zagari M. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int. 2004;65(3):757-67. (Pubitemid 38251052)
12. Marsh JT, Brown WS, Wolcott D, et al. rHuEPO treatment improves brain and cognitive function of anemia dialysis patients. Kidney Int. 1991;39(1):155-63.
13. Beusterien KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE Jr. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol. 1996;7(5):763-73. Available at: http://jasn.asnjournals.org/cgi/reprint/7/5/763. Accessed September 17, 2010.
14. Guthrie M, Cardenas D, Eschbach JW, Haley NR, Robertson HT, Evans RW. Effects of erythropoietin on strength and functional status of patients on hemodialysis. Clin Nephrol. 1993;39(2):97-102. (Pubitemid 23077808)
15. Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol. 1999;10(6):1309-16. Available at: http://jasn.asnjournals.org/cgi/reprint/10/6/1309. Accessed September 17, 2010.
16. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999;10(3):610-19. Available at: http://jasn.asnjournals.org/cgi/reprint/10/3/610. Accessed September 17, 2010.
17. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35(7):1737-44. Available at: http://content.onlinejacc.org/cgi/ reprint/35/7/1737.pdf. Accessed September 17, 2010.
18. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47(5 suppl 3):S11-S146. Available at: http://www.kidney.org/ professionals/kdoqi/guidelines-ANEMIA/index.htm. Accessed September 17, 2010.
19. U.S. Department of Health and Human Services, National Institute of Diabetes and Digestive and Kidney Diseases. Anemia in kidney disease and dialysis. October 2008. Available at: http://kidney.niddk.nih.gov/kudiseases/ pubs/pdf/anemia.pdf. Accessed September 17, 2010.
20. Eschbach JW. Iron therapy and the anemia of ESRD: historical perspective. Semin Dial. 1999;12(4):212-18.
21. Gotloib L, Silverberg D, Fudin R, Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol. 2006;19(2):161-67.
22. Hörl WH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol. 2007;18(2):382-93. Available at: http://jasn. asnjournals.org/cgi/reprint/18/2/382. Accessed September 17, 2010.
23. Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ, Besarab A. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol. 2006;26(5):445-54. (Pubitemid 44971735)
24. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S; for the United States Iron Sucrose (Venofer) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005;68(6):2846-56. Available at: http://www.nature.com/ki/journal/v68/n6/pdf/4495631a.pdf. Accessed September 17, 2010.
25. Charytan C, Qunibi W, Bailie GR; Venofer Clinical Studies Group: Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005;100(3):c55-c62. (Pubitemid 40868986)
26. Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant. 2001;16(5):967-74. Available at: http://ndt.oxfordjournals.org/cgi/reprint/16/5/ 967. Accessed September 17, 2010.
27. Dexferrum (iron dextran injection). American Regent. August 2008. Available at: http://www.americanregent.com/documents/ Product16PrescribingInformation.pdf. Accessed September 17, 2010.
28. Venofer (iron sucrose injection). American Regent. Available at: http://www.venofer.com/pdfs/Venofer%20IN2340%20Rev%2010-08.pdf. Accessed September 17, 2010.
29. Ferrlecit (sodium ferric gluconate complex in sucrose injection). sanofiaventis. January 2010. Available at: http://products.sanofi-aventis.us/ ferrlecit/ferrlecit.html. Accessed September 17, 2010.
30. Pfeffer MA, Burdmann EA, Chen CY, et al.; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019-32. Available at: http://www.nejm.org/doi/pdf/10.1056/ NEJMoa0907845. Accessed September 17, 2010.
31. Singh AK, Szczech L, Tang KL, et al.; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-98. Available at: http://www.nejm.org/doi/pdf/10.1056/ NEJMoa065485. Accessed September 17, 2010.
32. Drüeke TB, Locatelli F, Clyne N, et al.; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071-84. Available at: http://content.nejm. org/cgi/reprint/355/20/2071.pdf. Accessed September 17, 2010.
33. Aranesp. Amgen. May 2010. Available at: http://pi.amgen.com/united- states/aranesp/ckd/aranesp-pi-hcp-english.pdf. Accessed September 17, 2010.
34. Epogen. Amgen. February 2010. Available at: http://pi.amgen.com/united- states/epogen/epogen-pi-hcp-english.pdf. Accessed September 17, 2010.
35. Besarab A. Resolving the paradigm crisis in intravenous iron and erythropoietin management. Kidney Int Suppl. 2006;(101):S13-S18. (Pubitemid 44561638)
36. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20(9):1501-10. (Pubitemid 39361354)
37. Voormolen N, Grootendorst DC, Urlings TA, et al. Prevalence of anemia and its impact on mortality and hospitalization rate in predialysis patients. Nephron Clin Pract. 2010;115(2):c133-41.
38. Kammerer J, Ratican M, Elzein H, Mapes D. Anemia in CKD: prevalence, diagnosis, and treatment. Case study of the anemic patient. Nephrol Nurs J. 2002;29(4):371-74.
39. US Department of Health and Human Services. Centers for Medicare & Medicaid Services. Standard Analytic Files. Available at: https://www.cms.gov/ IdentifiableDataFiles/02-StandardAnalyticalFiles.asp. Accessed September 17, 2010.
40. U.S. Department of Labor. Bureau of Labor Statistics. Measuring price change for medical care in the CPI. April 12, 2010. Available at: http://www.bls.gov/cpi/cpifact4.htm. Accessed September 17, 2010.
41. Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents - time for a reevaluation. N Engl J Med. 2010;362(3):189-92. Available at: http://www.nejm.org/doi/pdf/10.1056/NEJMp0912328. Accessed September 17, 2010.
42. Center for Disease Control and Prevention. Prevalence of chronic kidney disease and associated risk factors - United States, 1999-2004. MMWR Morb Mortal Wkly Rep. 2007;56(8):161-65. Available at: http://www.cdc.gov/mmwr/preview/ mmwrhtml/mm5608a2.htm. Accessed September 17, 2010.